Is BMY overvalued right now?
A stock is overvalued when its market price sits above a reasonable fair value range. Use the live snapshot on this page for BMY, then validate with fundamentals and peer multiples.
Bristol-Myers Squibb Company (BMY) is currently Undervalued by 69.33%
Instant valuation answer
Bristol-Myers Squibb Company (BMY) appears undervalued by approximately 69.33% based on our live valuation percent and intrinsic value estimate derived from DCF, P/E Multiple, and P/S Multiple models. Valuation can still differ across analyst models, growth expectations, and risk assumptions.
- Upside (live) 69.33% (from live valuation API)
- Confidence (live) 9.5/10 (Very High)
Confidence Score is based on the magnitude of upside or downside vs intrinsic value.
Fair value estimate
Unlock fair valueCurrent price
$56.70
Stock valuation checker
Search our company database (same as the site header). Choose a result or type a ticker and press Check valuation.
Explore Our Valuation Calculators
Why is Bristol-Myers Squibb Company overvalued or undervalued?
Intrinsic value work anchors Bristol-Myers Squibb Company on owner earnings and balance-sheet capacity; the current quote trades below that anchor, which frames the stock as relatively cheap on a fundamentals-first view.
Versus historical valuation bands, BMY is closer to the lower end of where this business has traded when profitability and growth were comparable—useful context before reading any single headline multiple.
Forward market expectations are muted: the price does not require heroic assumptions to converge with our fair-value zone, but sector peers and macro rates still deserve a quick sanity check on the company page.
Key metrics
- P/E ratio
- 48.6x
- Revenue growth (TTM y/y)
- 25%
- Profit margin
- 29.1%
- Fair value (model)
- Unlock
Frequently asked questions — BMY
What is Bristol-Myers Squibb Company's intrinsic value?
Our DCF, P/E Multiple, and P/S Multiple models estimate whether BMY trades above or below fair value. At $56.70, Bristol-Myers Squibb Company currently looks undervalued on this snapshot. Tickerplace Pro unlocks the full dollar fair value estimate.
How is Bristol-Myers Squibb Company's intrinsic value calculated?
Tickerplace calculates BMY's fair value using Discounted Cash Flow (DCF), P/E Multiple, and P/S Multiple models. We compare the resulting intrinsic value estimate to the live market price to flag undervalued or overvalued positioning.
Is BMY undervalued right now?
Based on our 2026 valuation models, Bristol-Myers Squibb Company (BMY) appears undervalued at $56.70 with about 69.3% upside to fair value. Treat this as a screen—verify fundamentals on the company profile.
Related companies — valuation
Peers for BMY: open their overvalued / undervalued view.